TY - JOUR
T1 - Hormone supplementation differently affects migraine in postmenopausal women
AU - Facchinetti, F.
AU - Nappi, R. E.
AU - Tirelli, A.
AU - Polatti, F.
AU - Nappi, G.
PY - 2002/10
Y1 - 2002/10
N2 - Objective. To evaluate the effects of three schemes of oral hormone replacement therapy (HRT) on migraine course in postmenopausal women. Methods. Thirty-eight patients presenting for clinical evaluation of menopausal status and suffering from migraine were enrolled. The observational period lasted 7 months, during which women filled in a daily diary with the clinical features of headache attacks and analgesic use. We evaluated climacteric symptoms, anxiety and depression. After a 1-month run-in period, women were assigned to one of three regimens of HRT: estradiol hemihydrate 1 mg/day plus norethisterone 0.5 mg/day for 28 days, in a continuous combined scheme; oral conjugated estrogens 0.625 mg/day for 28 days plus medroxyprogesterone acetate 10 mg/day in the last 14 days, in a sequential continuous scheme; and estradiol valerate 2 mg/day for 21 days plus cyproterone acetate 1 mg/day from day 12 to 21 in a sequential cyclical scheme. Follow-up evaluations were performed at 3 and 6 months. Results. During the run-in period, the three subgroups of patients were similar as far as the features of migraine are concerned. Overall, a progressive increase in attack frequency (from 2.2 ± 1.0 to 3.8 ± 1.3, P
AB - Objective. To evaluate the effects of three schemes of oral hormone replacement therapy (HRT) on migraine course in postmenopausal women. Methods. Thirty-eight patients presenting for clinical evaluation of menopausal status and suffering from migraine were enrolled. The observational period lasted 7 months, during which women filled in a daily diary with the clinical features of headache attacks and analgesic use. We evaluated climacteric symptoms, anxiety and depression. After a 1-month run-in period, women were assigned to one of three regimens of HRT: estradiol hemihydrate 1 mg/day plus norethisterone 0.5 mg/day for 28 days, in a continuous combined scheme; oral conjugated estrogens 0.625 mg/day for 28 days plus medroxyprogesterone acetate 10 mg/day in the last 14 days, in a sequential continuous scheme; and estradiol valerate 2 mg/day for 21 days plus cyproterone acetate 1 mg/day from day 12 to 21 in a sequential cyclical scheme. Follow-up evaluations were performed at 3 and 6 months. Results. During the run-in period, the three subgroups of patients were similar as far as the features of migraine are concerned. Overall, a progressive increase in attack frequency (from 2.2 ± 1.0 to 3.8 ± 1.3, P
KW - Hormones
KW - Migraine
KW - Postmenopause
UR - http://www.scopus.com/inward/record.url?scp=0036806490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036806490&partnerID=8YFLogxK
U2 - 10.1046/j.1526-4610.2002.02215.x
DO - 10.1046/j.1526-4610.2002.02215.x
M3 - Article
C2 - 12390622
AN - SCOPUS:0036806490
VL - 42
SP - 924
EP - 929
JO - Headache
JF - Headache
SN - 0017-8748
IS - 9
ER -